Transforming Prostate Cancer Care, Together
Stratify Prostate™ enables physicians to order no-cost tumor sequencing for their patients with metastatic prostate cancer. By expanding access to NGS testing, we seek to accelerate enrollment of men with advanced prostate cancer onto precision oncology trials.
Today, we are targeting patient enrollment on studies evaluating the PARP inhibitor rucaparib in the TRITON2 and TRITON3 trials. As we gather more genomic data, our goal is also to catalyze new studies for patients harboring other targetable alterations.
StrataNGS™ - Tumor Sequencing Test
StrataNGS is a tumor sequencing test performed in Strata Oncology’s high-throughput CLIA-certified laboratory in Ann Arbor, MI. StrataNGS targets 87 genes by sequencing DNA and RNA from limited formalin-fixed paraffin-embedded tumor material. The test was designed to detect clinically actionable genetic variants for which there are associated approved therapies or clinical trials.
Results include Microsatellite instability (MSI) status, which may help predict response to immunotherapy.
The StrataNGS test was based in part on the Strata team's prior development and validation of the Oncomine Cancer Panel (1), which was also the basis for the National Cancer Institute's MATCH assay (2).
1. Hovelson DH, et al. Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. Neoplasia. 2015 Apr;17(4):385-99
How does Stratify Prostate work?
1. Create a Physician Account
Physicians caring for men with metastatic prostate cancer in the United States can create a physician account to begin ordering StrataNGS tests immediately. After your credentials are validated, Strata staff will send you test ordering instructions, sample collection kits and login information for the Physician Portal.
2. Order StrataNGS Test
Tests are ordered online by physicians through our secure Physician Portal, and the patient's leftover tumor material is shipped to Strata Oncology for testing. A formalin-fixed paraffin-embedded tumor block or slides are required. No payment or billing information is required.
3. Review Test Report
Test reports are delivered online to ordering physicians within 7-10 business days. Positive and negative genomic alterations are reported and associated FDA-approved therapies and clinical trials are noted.
Stratify Prostate is made possible by physicians who order the StrataNGS test as part of a minimal risk observational study – The Strata Trial (NCT03061305), sponsored by Strata Oncology. This study has been reviewed and approved by Chesapeake IRB. The aim of the study is to better understand the frequency of tumor mutations in metastatic cancer and the utility of tumor genome testing in selecting treatments and clinical trials. The study is conducted virtually and no patient interaction with study staff is required. In some cases, the study team may contact the provider to document treatment selection.
Call us at 734-527-1000 or email firstname.lastname@example.org